Genmab — Marts 2019

[Helge_LarsenPI-redaktør]

God morgen.

[bibob]

God morgen.

[bibob]

GSK / BCMA drug med gode resultater. https://m.firstwordpharma.com/glaxosmithkline-targets-regulatory-filings-year-end-anti-bcma-drug-gsk2857916-multiple-myeloma

[Helge_LarsenPI-redaktør]

"
Meanwhile, among Darzalex-experienced patients, the drugmaker said the ORR and median PFS were 38.5 percent and 7.9 months, respectively. GlaxoSmithKline noted that no new safety signals were observed in the study".

[transalp]

Go morgen : )

[StockBull]

Morn. Rısıng wedge ındıkere bullısh stıgnıng mod / gennem modstanden ı 1189

[jkj]

hvis det er direkte sammenlignelige tal, så er det vel ikke så godt for dara. ?

[polle1]

Godmorgen og god dag

[E_L]

read back the nov Q3 transcript back, answer to Citi analyst on BCMA. eg: Jan: actually, we were actually delighted to see the updated data. We don't feel very threatened by them at all

[E_L]

"And what is also encouraging is that Janssen recently, they also have a BCMA CD3 bispecific program using our DuoBody technology….& said in the business update that they intend to actually combine their BCMA CD3 bispecific together with daratumumab and not compete with daratumumab, and that is probably the right thing to do also for the BCMA ADC from Glaxo and potentially for Amgen's BCMA BiTE molecule."

[peter12]

Det var det EL linkede til i onsdags. Det er et lille studie (n=35) og kun friske patienter, da det nok er for giftigt til svagere...

[Helge_LarsenPI-redaktør]

Tak for reminderen E L.

[gentogen]

Lidt svært helt at gennemskue, men 54% af patienterne var "Stage I" og alle ECOG 0 eller 1 (70% 1). Tidligere behandlinger fra 1 til over 10. 14 en eller anden slags Dara behandling tidligere. Safety lidt svær at vurdere da procenterne er procenter af alle, selv om kun 22 af 35 gennemførte (så tallene kan være for små - måske). De fremhæver selv at dette er det hidtil bedste, der er set efter Dara

[E_L]

Genmab Announces European Regulatory Submission for Daratumumab in Combination with Lenalidomide and Dexamethasone in Frontline Multiple Myeloma

Company Announcement Type II variation application submitted to the EMA for daratumumab in combination with lenalidomide and dexamethasone as treatment...

GlobeNewswire News Room (www.globenewswire.com)

[E_L]

Genmab Announces European Regulatory Submission for Daratumumab in Combination with Lenalidomide and Dexamethasone in Frontline Multiple Myeloma

[Sukkeralf]

Nice

[E_L]

it remains strange to me that there is such a difference between US and european treatment regimen. I wonder if some day we'll see a head-to-head MAIA-Alcyone trial?

[peter12]

Now you can buy generic Revlimid in some european countries ?

[jkj]

Hvornår var det helt præcist at jannsen aflevere sidste data til fda ?

[jkj]

herfra skal vi vel regne med 4 uger ifølge rtor planen eller hvad ?